---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: C1 esterase inhibitor concentrates"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: C1 esterase inhibitor concentrates. Topics: Plasma-derived C1 inhibitor: indication, dose, and self-administration; Plasma-derived C1 inhibitor: laryngeal attacks, thromboembolism, and infectious risk; Plasma-derived C1 inhibitor 20 IU/kg versus placebo: randomized clinical trial in the label; Plasma-derived C1 inhibitor 10 or 20 U/kg versus placebo: published randomized trial in 125 participants; 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/c1-esterase-inhibitor-concentrates"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: C1 esterase inhibitor concentrates

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 C1 Esterase Inhibitor Concentrates

<a id="topic-2.2.2.1.1-1"></a>

### Plasma-derived C1 inhibitor: indication, dose, and self-administration

> “BERINERT is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.”
> “The safety and efficacy of BERINERT for prophylactic therapy have not been established.”
> “Administer BERINERT at a dose of 20 International Units (IU) per kg body weight by intravenous injection. Doses lower than 20 IU/kg body weight should not be administered.”
> “Inject at a rate of approximately 4 mL per minute.”
> “For self-administration, provide the patient with instructions and training for intravenous injection outside of a clinic setting so patients may self-administer BERINERT upon recognition of symptoms of an HAE attack”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### Plasma-derived C1 inhibitor: laryngeal attacks, thromboembolism, and infectious risk

> “Given the potential for airway obstruction during acute laryngeal HAE attacks, patients self-administering BERINERT should be advised to immediately seek medical attention in an appropriate healthcare facility after treatment with BERINERT.”
> “Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including BERINERT, following administration in patients with HAE.”
> “Because BERINERT is made from human blood, it may carry a risk of transmitting infectious agents”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-3"></a>

### Plasma-derived C1 inhibitor 20 IU/kg versus placebo: randomized clinical trial in the label

> “The RCT assessed the efficacy and safety of BERINERT in 124 adult and pediatric subjects with C1 esterase inhibitor deficiency who were experiencing an acute moderate to severe attack of abdominal or facial HAE.”
> “Subjects were randomized to receive a single 10 IU/kg body weight dose of BERINERT (39 subjects), a single 20 IU/kg dose of BERINERT (43 subjects), or a single dose of placebo (42 subjects)”
> “in time to onset of relief from symptoms of an HAE attack as compared to placebo (median of 48 minutes for BERINERT 20 IU/kg body weight, as compared to a median of >4 hours for placebo).”
> “No subjects treated with BERINERT at 20 IU/kg body weight reported worsening of symptoms at 4 hours after administration of study medication compared to baseline.”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### Plasma-derived C1 inhibitor 10 or 20 U/kg versus placebo: published randomized trial in 125 participants

> “This was a randomized, double-blind, placebo-controlled study in 125 patients with type I or II hereditary angioedema.”
> “Median time to onset of relief was significantly shorter with C1 esterase inhibitor concentrate at a dose of 20 U/kg than with placebo (0.5 vs 1.5 hours; P = .0025), whereas with 10 U/kg, the time to onset of relief was only slightly shorter than with placebo (1.2 vs 1.5 hours; P = .2731).”
> “Compared with placebo, the reduction in time to onset of relief was greatest for severe attacks (0.5 vs 13.5 hours).”

Source: [Craig et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19767078/)

<a id="topic-2.2.2.1.1-5"></a>

### Plasma-derived C1 inhibitor for laryngeal attacks: open-label extension in the label

> “BERINERT was evaluated in a prospective, open-label, uncontrolled, multicenter extension study conducted at 15 centers in the US and Canada”
> “During the extension study, 51 subjects experienced 747 abdominal attacks, 21 subjects experienced 51 facial HAE attacks, 30 subjects experienced 235 peripheral HAE attacks, and 16 subjects experienced 48 laryngeal HAE attacks.”
> “An analysis of laryngeal HAE attacks showed that the median time to initial onset of symptom relief and median time to complete resolution in the per-attack analysis were 0.25 hours and 8.4 hours, respectively”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-6"></a>

### Recombinant human C1 inhibitor: indication, dose, redosing limit, and contraindication

> “RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).”
> “Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.”
> “The recommended dose of RUCONEST is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.”
> “If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level. Do not exceed 4200 U per dose. No more than two doses should be administered within a 24-hour period.”
> “RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products.”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### Recombinant human C1 inhibitor 50 U/kg versus placebo: Study 1 in the label

> “Seventy-five (75) adults and adolescent patients were randomized (3:2) to receive RUCONEST 50 U/kg (N = 44) or placebo (N = 31).”
> “In the RCT phase, the median time to beginning of relief of symptoms was statistically significantly shorter in patients treated with RUCONEST 50 U/kg compared with patients treated with placebo as assessed by the TEQ”
> “Among patients who achieved relief within 4 hours, there were 4 (27%) patients in the placebo group who had a relapse of their symptoms within 24 hours as compared with 1 (3%) in the RUCONEST group.”
> “Life-threatening laryngeal attacks were excluded from the randomized-controlled phase of Study 1”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

> “Seventy-five patients experiencing peripheral, abdominal, facial, and/or oropharyngeal laryngeal attacks were randomized (3:2) to rhC1INH (n = 44) or placebo (saline; n = 31).”
> “Median (95% confidence interval) time to beginning of symptom relief at the primary attack location was 90 minutes (61-150) in rhC1INH-treated patients vs 152 minutes (93, not estimable) in placebo-treated patients (P = .031) based on the TEQ”
> “Overall, rhC1INH was safe and well tolerated; no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed.”

Source: [Riedl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24468257/)

<a id="topic-2.2.2.1.1-8"></a>

### Recombinant human C1 inhibitor 50 or 100 U/kg versus saline: pooled analysis of two randomized trials

> “Two similar independent, randomized, saline controlled, double-blind studies were conducted to evaluate the efficacy and safety of recombinant human C1-inhibitor (rhC1INH) as a treatment of acute angioedema attacks in patients with HAE.”
> “rhC1INH at 100 (n = 29) and 50 (n = 12) U/kg body weight resulted in a significant reduction for both the primary endpoint time to the beginning of relief of symptoms compared with saline (n = 29): median, 66 (95% CI, 61-122) minutes, 122 (72-136) minutes, and 495 (245-520) minutes, P < .001 and P = .013, respectively”
> “Therapeutic failure occurred in 59% (17/29) of the saline group compared with 0% (0/12) of the 50 U/kg group and 10% (3/29) of the 100 U/kg group.”

Source: [Zuraw et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20920772/)

<a id="topic-2.2.2.1.1-9"></a>

### Intravenous C1 inhibitor as a first-line on-demand treatment: guideline recommendations

> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide”
> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”
> “It is commercially available in 2 plasma-derived concentrates and 1 recombinant human product for intravenous administration.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that attacks are treated with either intravenous C1 inhibitor, ecallantide, or icatibant.”
> “For on-demand treatment, only the intravenous application of C1–INH is effective.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Effective therapies include ecallantide, icatibant, intravenous C1INH (plasma-derived or recombinant), and sebetralstat.”
> “It is administered intravenously either by healthcare professionals or by patients or caregivers who have been trained in its administration”
> “pdC1INH continues to play an important role in the treatment of attacks in patients with HAE due to C1INH deficiency”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.1-10"></a>

### Dose rounding, half-life, and rabbit allergy: guideline statements

> “When pdC-1INH is used, it should be administered at a dose of 20 IU/kg, rounded to the nearest 500 IU (as vials contain 500 IU) to minimize product waste.”
> “rC1-INH is produced through genetic engineering, and because it is secreted in the milk of transgenic rabbits, it is contraindicated in patients with a known allergy to rabbits.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “The mean plasma half-life of pdC1-INH is longer than 30 h.”
> “It appears that differential glycosylation of Ruconest relative to the human protein decreases the plasma half-life to approximately 3 h.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.1-11"></a>

### Plasma-derived C1 inhibitor in pregnancy and in children: guideline recommendations

> “Plasma-derived C1-INH is considered safe and effective for on-demand treatment of HAE attacks during pregnancy, whereas all other drugs are off-label alternatives.”
> “For pregnant patients with HAE, we recommend first-line ODT with IV pdC1-INH.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “In neonates and infants with hereditary angioedema due to C1 inhibitor deficiency between birth and 2 years, we recommend the use of intravenous plasma‐derived C1 inhibitor concentrate as first‐line therapy for acute treatment of angioedema attacks.”
> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
